Our new AI assistant can help patients, caregivers, and researchers find important information faster. Click the logo in the lower right corner to try it.
Fibrolamellar carcinoma (FLC) is driven by a unique fusion protein called DNAJB1::PRKACA (DP). This fusion is responsible for the growth of the tumor cells, and without it, the tumor dies. Unfortunately, targeting this fusion with drugs has proven extremely difficult, because the fusion’s active site is almost identical to that of normal protein kinase A …
Fibrolamellar carcinoma (FLC) is a rare, aggressive liver cancer affecting adolescents and young adults. Nearly all cases contain the same genetic abnormality — a fusion protein called DNAJ‑PKAc. This study provides clear evidence that the fusion protein fundamentally reshapes both the metabolism of the cancer and immune behavior. Importantly, this rewiring reveals a specific therapeutic …
Fibrolamellar carcinoma (FLC) is a rare liver cancer that mostly affects young people and currently has no standard, effective treatment. Over the last decade, many studies have been conducted that have analyzed multiple types of biological data from the same cells or tissue to get a more complete picture of how the disease works, but …
This study explored how fibrolamellar carcinoma (FLC) rewires the way its cells generate energy, focusing on calcium inside mitochondria—the cell’s “power plants.” Researchers found that FLC cells have abnormally high mitochondrial calcium levels, which changes how they process nutrients like branched‑chain amino acids. A key driver of this is the mitochondrial calcium uniporter, a channel …
This in-depth description of a Phase 1 clinical trial initiated in April 2020 provides strong initial evidence for the safety and efficacy of a therapeutic vaccine against fibrolamellar carcinoma (FLC). The vaccine was given in combination with two immune checkpoint inhibitors (ICIs) already approved for use against many cancers. Published in the prestigious journal Nature …